These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 14631268)

  • 21. Disease stage in Alzheimer disease and treatment effects of rivastigmine.
    Kurz A; Farlow M; Quarg P; Spiegel R
    Alzheimer Dis Assoc Disord; 2004; 18(3):123-8. PubMed ID: 15494617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease.
    Potki SG; Anand R; Hartman R; Veach J; Grossberg G
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 May; 26(4):713-20. PubMed ID: 12188104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rivastigmine for Alzheimer's disease.
    Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
    Potkin SG; Anand R; Fleming K; Alva G; Keator D; Carreon D; Messina J; Wu JC; Hartman R; Fallon JH
    Int J Neuropsychopharmacol; 2001 Sep; 4(3):223-30. PubMed ID: 11602028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.
    Cummings J; Emre M; Aarsland D; Tekin S; Dronamraju N; Lane R
    J Alzheimers Dis; 2010; 20(1):301-11. PubMed ID: 20164585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
    Zhang ZX; Hong Z; Wang YP; He L; Wang N; Zhao ZX; Zhao G; Shang L; Weisskopf M; Callegari F; Strohmaier C
    CNS Neurosci Ther; 2016 Jun; 22(6):488-96. PubMed ID: 27012596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications.
    Baladi JF; Bailey PA; Black S; Bouchard RW; Farcnik KD; Gauthier S; Kertesz A; Mohr E; Robillard A
    Clin Ther; 2000 Dec; 22(12):1549-61. PubMed ID: 11192146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.
    Feldman HH; Lane R;
    J Neurol Neurosurg Psychiatry; 2007 Oct; 78(10):1056-63. PubMed ID: 17353259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
    Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
    J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
    Farlow M; Anand R; Messina J; Hartman R; Veach J
    Eur Neurol; 2000; 44(4):236-41. PubMed ID: 11096224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
    Almkvist O; Darreh-Shori T; Stefanova E; Spiegel R; Nordberg A
    Eur J Neurol; 2004 Apr; 11(4):253-61. PubMed ID: 15061827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Mauskopf JA
    Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.
    Farlow MR; Cummings JL; Olin JT; Meng X
    Am J Alzheimers Dis Other Demen; 2010 Jun; 25(4):347-52. PubMed ID: 20392862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Alzheimer disease: efficacy and tolerance of rivastagmine].
    Hébert M
    Presse Med; 1999 Oct; 28(32):1757-8. PubMed ID: 10566280
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
    Erkinjuntti T; Skoog I; Lane R; Andrews C
    Int J Clin Pract; 2002 Dec; 56(10):791-6. PubMed ID: 12510954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.